Neratinib Alone or in Combination with Immune Checkpoint Inhibitors with or without Mammalian Target of Rapamycin Inhibitors in Patients with Fibrolamellar Carcinoma
Sign Up to like & getrecommendations! Published in 2024 at "Liver Cancer"
DOI: 10.1159/000540290
Abstract: Abstract Introduction: Fibrolamellar carcinoma (FLC) displays upregulation of several oncogenes, including HER2, and multiple immune-suppressive mechanisms. We investigated the efficacy and safety of the pan-HER tyrosine kinase inhibitor neratinib as monotherapy (SUMMIT phase 2 basket… read more here.
Keywords: received neratinib; summit; immune checkpoint; plus pembrolizumab ... See more keywords